Supplemental Material

Improvements in Lung Function with Nebulized Revefenacin in the Treatment of Patients with Moderate-to-Very Severe COPD: Results from Two Replicate Phase III Clinical Trials

Gary T. Ferguson, MD¹ Gregory Feldman, MD² Krishna K. Pudi, MD³ Chris N. Barnes, PhD⁴ Edmund J. Moran, PhD⁴ Brett Haumann, MD, MBA⁴ Srikanth Pendyala, MD⁴ Glenn Crater, MD⁴

¹Pulmonary Research Institute of Southeast Michigan, Farmington Hills

²South Carolina Pharmaceutical Research, Spartanburg

³Sherman Clinical Research, Sherman, Texas

⁴Theravance Biopharma US, Inc., South San Francisco, California

Methods

Secondary endpoints


OTE trough FEV₁ during the 12-week studies was a key secondary endpoint of Studies 0126 and 0127. The OTE trough FEV₁ is a metric of both the persistence and consistency of the treatment effect over the 12-week treatment duration, placing emphasis on the entire dosing period, as opposed to only the last assessment day, at which point the number of subjects being evaluated is smallest due to drop out. Mathematically, the OTE is an inverse weighted mean of observed FEV_1 troughs that places a higher weight on more informative (e.g., less variance) time points, relative to using a single time point (end of study) to make an inference on treatment effect at the end of treatment, when the least number of subjects are still on study due to subject withdrawal.

Statistical Analyses


A mixed-effect repeated-measures model was used to evaluate the primary FEV_1 endpoint. The model included fixed effect class terms for treatment group, smoking status (current or former

smoker), reversibility status (not reversible to either ipratropium or albuterol, reversible to albuterol but not to ipratropium, reversible to ipratropium but not to albuterol or reversible to both ipratropium and albuterol), concomitant LABA use at baseline (yes or no), sex (male or female) and age at baseline (≤ 65 years or ≥ 65 years). Missing data were assumed to be missing at random. The missing at random assumption was evaluated using both 1- and 2-dimensional tipping point multiple imputation and found to be valid.

To evaluate the consistency of treatment effects on trough FEV₁ across a wide range of the ITT population, sub-group analyses were conducted on pooled Study 0126 and 0127 results. Trough FEV₁ sub-group analysis included patient segmentation by age group (\geq 65 years), LABA use, ICS use, 2011 GOLD category D¹⁷ (indicating symptomatic patients with significant airflow limitation) and those scoring <2 on the Modified Medical Research Council dyspnea scale. A similar model used for trough FEV₁ was used for peak FEV₁. The OTE trough FEV₁ was computed by deriving a set of inverse-weights and applying those weights to the predicted values for trough FEV₁ from the primary analysis model. A t-test was used to derive statistical significance.



Supplemental Figure. 1 Study design. During Visit 1A, patients were issued study-specific rescue medication (an albuterol metereddose inhaler) that they were permitted to use on an as-needed basis during the treatment period. Next, they underwent a washout period from prohibited medications, including all LAMA-containing products. Once sufficient patients receiving concomitant LABAs had been enrolled (up to 40% of the study population), the washout period for the remaining enrolled patients also pertained to all LABA-containing products. After the washout period, patients were required to attend 2 screening visits (Visits 1B and 2), 6 treatment visits (Visits 3-8) and a follow-up visit (Visit 9). Patients underwent ipratropium reversibility testing during Visit 1B and albuterol reversibility testing at Visit 2. ECG: electrocardiogram; LABA: long-acting beta agonist; LAMA: long-acting muscarinic antagonist; PK: pharmacokinetic; PROs: patient-reported outcomes.



Supplemental Figure 2. Baseline COPD severity in Studies 0126 and 0127. COPD severity of participants in Studies 0126 and 0127 was determined according to severity of airflow limitation^a (upper panels) and symptoms and risk of exacerbations^b (lower panels) using 2011 GOLD criteria. ^aGOLD severity of airflow limitation: 1 = mild, 2 = moderate, 3 = severe, 4 = very severe. ^bGOLD symptoms and risk of exacerbations: A = less symptoms, low risk; B = more symptoms, low risk; C = less symptoms, high risk; D = more symptoms, high risk. COPD: chronic obstructive pulmonary disease; GOLD: Global Initiative for Chronic Obstructive Lung Disease.